DK0861235T3 - Substituerede benzylaminopiperidinforbindelser - Google Patents

Substituerede benzylaminopiperidinforbindelser

Info

Publication number
DK0861235T3
DK0861235T3 DK96914375T DK96914375T DK0861235T3 DK 0861235 T3 DK0861235 T3 DK 0861235T3 DK 96914375 T DK96914375 T DK 96914375T DK 96914375 T DK96914375 T DK 96914375T DK 0861235 T3 DK0861235 T3 DK 0861235T3
Authority
DK
Denmark
Prior art keywords
compounds
substituted
substituted benzylaminopiperidine
benzylaminopiperidine compounds
benzylaminopiperidine
Prior art date
Application number
DK96914375T
Other languages
English (en)
Inventor
Kunio Satake
Yuji Shishido
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0861235T3 publication Critical patent/DK0861235T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96914375T 1995-08-24 1996-06-10 Substituerede benzylaminopiperidinforbindelser DK0861235T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24
PCT/IB1996/000572 WO1997008144A1 (en) 1995-08-24 1996-06-10 Substituted benzylaminopiperidine compounds

Publications (1)

Publication Number Publication Date
DK0861235T3 true DK0861235T3 (da) 2001-12-27

Family

ID=11004362

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96914375T DK0861235T3 (da) 1995-08-24 1996-06-10 Substituerede benzylaminopiperidinforbindelser
DK01108350T DK1114817T3 (da) 1995-08-24 1996-06-10 Substituerede benzylaminopiperidinforbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK01108350T DK1114817T3 (da) 1995-08-24 1996-06-10 Substituerede benzylaminopiperidinforbindelser

Country Status (41)

Country Link
US (1) US6506775B1 (da)
EP (2) EP0861235B1 (da)
JP (1) JP3084069B2 (da)
KR (1) KR100288673B1 (da)
CN (1) CN1153764C (da)
AP (1) AP643A (da)
AR (1) AR006305A1 (da)
AT (2) ATE258166T1 (da)
AU (1) AU702698B2 (da)
BG (1) BG64126B1 (da)
BR (1) BR9609989A (da)
CA (1) CA2227814C (da)
CO (1) CO4480738A1 (da)
CZ (1) CZ297543B6 (da)
DE (2) DE69616817T2 (da)
DK (2) DK0861235T3 (da)
DZ (1) DZ2086A1 (da)
ES (2) ES2163017T3 (da)
HR (1) HRP960386B1 (da)
HU (1) HU225480B1 (da)
IL (1) IL119078A (da)
IS (1) IS1947B (da)
MA (1) MA23961A1 (da)
MX (1) MX9801467A (da)
MY (1) MY114800A (da)
NO (1) NO310720B1 (da)
NZ (1) NZ308207A (da)
OA (1) OA10666A (da)
PE (2) PE20010700A1 (da)
PL (1) PL186773B1 (da)
PT (2) PT1114817E (da)
RO (1) RO119299B1 (da)
RU (1) RU2152930C2 (da)
SI (2) SI1114817T1 (da)
SK (1) SK282925B6 (da)
TN (1) TNSN96107A1 (da)
TR (1) TR199800300T1 (da)
TW (1) TW340842B (da)
UA (1) UA48981C2 (da)
WO (1) WO1997008144A1 (da)
YU (1) YU49122B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
HRP20010821A2 (en) * 1999-05-06 2002-12-31 Pfizer Prod Inc Substituted benzolactam compounds
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
EP1178984B1 (en) * 1999-05-21 2003-03-19 Pfizer Products Inc. 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
EP1095939B1 (en) * 1999-10-18 2004-01-07 Pfizer Products Inc. Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
WO2001032625A1 (en) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
US6407235B1 (en) * 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
EP1753722A2 (en) * 2004-05-21 2007-02-21 Pfizer Products Inc. Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
JP5511080B2 (ja) 2008-03-31 2014-06-04 興和株式会社 １，３−ジヒドロイソベンゾフラン誘導体
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699567A1 (en) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
DK2925888T3 (da) 2012-11-28 2017-12-18 Merck Sharp & Dohme Sammensætninger og fremgangsmåder til behandling af cancer
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
JPH0794440B2 (ja) * 1991-03-26 1995-10-11 フアイザー・インコーポレイテツド 置換ピペリジンの立体選択的製造
HU224443B1 (hu) * 1991-06-20 2005-09-28 Pfizer Inc. Fluor-alkoxi-benzaldehid-származékok
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
KR19980703354A (ko) 1995-03-27 1998-10-15 나카토미히로타카 피페리딘 유도체
DE69623580T2 (de) * 1995-12-21 2003-01-09 Pfizer Inc., New York 3-((5-Substituierte Benzyl)Amino)-2-Phenylpiperidine als Substance-P-Antagonisten
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
AP643A (en) 1998-04-24
EP1114817A1 (en) 2001-07-11
KR19990044077A (ko) 1999-06-25
CN1193961A (zh) 1998-09-23
US6506775B1 (en) 2003-01-14
YU49122B (sh) 2004-03-12
TW340842B (en) 1998-09-21
DK1114817T3 (da) 2004-04-26
ATE258166T1 (de) 2004-02-15
HUP9901159A3 (en) 2000-05-29
DE69616817D1 (de) 2001-12-13
JP3084069B2 (ja) 2000-09-04
OA10666A (en) 2002-11-25
PT861235E (pt) 2002-03-28
MA23961A1 (fr) 1997-04-01
HRP960386A2 (en) 1998-04-30
CO4480738A1 (es) 1997-07-09
IL119078A (en) 2003-11-23
DE69631390T2 (de) 2004-11-25
RO119299B1 (ro) 2004-07-30
SK20798A3 (en) 1999-03-12
HRP960386B1 (en) 2002-04-30
PE20010700A1 (es) 2001-07-09
TR199800300T1 (xx) 1998-06-22
CA2227814C (en) 2002-12-31
CZ297543B6 (cs) 2007-02-07
TNSN96107A1 (fr) 2005-03-15
HK1014935A1 (en) 1999-10-08
ES2211684T3 (es) 2004-07-16
AR006305A1 (es) 1999-08-25
SI1114817T1 (en) 2004-06-30
BG102288A (en) 1998-09-30
PL186773B1 (pl) 2004-02-27
JPH10510554A (ja) 1998-10-13
EP0861235A1 (en) 1998-09-02
UA48981C2 (uk) 2002-09-16
CN1153764C (zh) 2004-06-16
KR100288673B1 (ko) 2001-05-02
BR9609989A (pt) 1999-07-06
WO1997008144A1 (en) 1997-03-06
BG64126B1 (bg) 2004-01-30
ES2163017T3 (es) 2002-01-16
EP0861235B1 (en) 2001-11-07
AU5776996A (en) 1997-03-19
DE69631390D1 (de) 2004-02-26
EP1114817B1 (en) 2004-01-21
NO310720B1 (no) 2001-08-20
NO980751D0 (no) 1998-02-23
HU225480B1 (en) 2006-12-28
NZ308207A (en) 1998-07-28
DE69616817T2 (de) 2002-04-04
IL119078A0 (en) 1996-11-14
PE1398A1 (es) 1998-02-27
CZ52198A3 (cs) 1999-01-13
AP9600850A0 (en) 1996-10-31
IS4644A (is) 1997-12-30
CA2227814A1 (en) 1997-03-06
YU47896A (sh) 1998-12-23
RU2152930C2 (ru) 2000-07-20
PL325332A1 (en) 1998-07-20
DZ2086A1 (fr) 2002-07-22
SI0861235T1 (en) 2002-04-30
MX9801467A (es) 1998-05-31
SK282925B6 (sk) 2003-01-09
MY114800A (en) 2003-01-31
PT1114817E (pt) 2004-05-31
HUP9901159A2 (hu) 1999-07-28
ATE208377T1 (de) 2001-11-15
NO980751L (no) 1998-02-23
AU702698B2 (en) 1999-03-04
IS1947B (is) 2004-10-13

Similar Documents

Publication Publication Date Title
DK1114817T3 (da) Substituerede benzylaminopiperidinforbindelser
ID16345A (id) Senyawa-senyawa heterosiklik
BR9607097A (pt) Novos compostos
FI20030370L (fi) Uusia yhdisteitä
DE59609887D1 (de) Substituierte cyanophenyluracile
DK0777671T3 (da) Spiro-azabicykliske forbindelser
FI971260A7 (fi) 1-asyyli-4-alifatyyliaminopiperidiiniyhdisteet
DE69608259D1 (de) Verbunddamenbinde
BR9600251A (pt) Composto
DE69630414D1 (de) 5B4T-Kodierungsschema
IS4739A (is) Efnasambönd
NO974170D0 (no) Polyazacykloalkan-forbindelser
DE59610332D1 (de) Substituierte aminouracile
FI970151A0 (fi) Viruksenvastaisesti vaikuttavia difluoristatoniyhdisteitä
BR9601295A (pt) Composto
BR9609319A (pt) Carbonilaminofeniluracilas substituídas
BR9608890A (pt) N-metilenotiouréias substituídas
BR9611576A (pt) Composto
ATE198470T1 (de) Alkenyl-benzoylguanidine
BR9603376A (pt) Tetrahidro-5-nitro-pirimidinas substituídas
DE59607732D1 (de) Substituierte benzylidencyanessigester
FI971971A7 (fi) Pyridatsinokinoliiniyhdisteitä
ID18956A (id) Senyawa-senyawa herbisida
DE59607958D1 (de) Substituierte phenyluracile
ITMI950031A0 (it) Composti dibenzoalchilenici